Key result
Early inhibition of natriuresis with fludrocortisone acetate significantly reduced the frequency of symptomatic vasospasm compared to delayed treatment (6.1% vs 18.5%) in patients with aneurysmal SAH.
Why the study?
Does early inhibition of natriuresis with fludrocortisone acetate prevent symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage?
Cohort (n=103)
Does early inhibition of natriuresis with fludrocortisone acetate prevent symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage?
Absolute Event Rate: 6.1% vs 18.5%
Early inhibition of natriuresis with fludrocortisone acetate before the onset of hyponatremia significantly reduces the incidence of symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
No takes yet. Share an insight, caveat, or question.
May support early fludrocortisone in aneurysmal SAH; hypothesis-generating and requires randomized confirmation before practice change.
Nakagawa et al. (2013) conducted a cohort in Aneurysmal subarachnoid hemorrhage (n=103). Early inhibition of natriuresis with fludrocortisone acetate vs. Treatment to correct electrolyte disorder after hyponatremia had occurred was evaluated on Symptomatic vasospasm (SVS). Early inhibition of natriuresis with fludrocortisone acetate significantly reduced the frequency of symptomatic vasospasm compared to delayed treatment (6.1% vs 18.5%) in patients with aneurysmal SAH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: